ERBB2 and breast carcinoma: Of the 24 breast cancer patients with PIK3CA mutation‐positive metastasis, 92% were ER‐positive (n = 22), 8% were ER‐negative (n = 2), and 8% were HER2‐amplified (n = 2) (Table 1).